Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTI idebenone withdrawal study in Friedreich's ataxia
NL-OMON36407Phase 3Active, not recruiting
- Sponsor
- Santhera Pharmaceuticals
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Friedreich ataxia (FA) comparing Idebenone continuation with Placebo withdrawal (2 arms). Primary endpoint: Patient assessment of treatment assignment. Started Aug 2011; status: active, not recruiting.
02
Drugs
idebenone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NL-OMON36407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36407.